Isotechnika, Cellgate sign option agreement for topical delivery of ISA247 for psoriasis

By Lisa Kerner

Erie, Pa., April 25 - Under an agreement with Cellgate Inc., Isotechnika Inc. has the option to obtain an exclusive license to develop conjugates of Cellgate's patented transporter technology for the topical delivery of ISA247 in patients suffering from mild to moderate psoriasis.

For its part, Cellgate will evaluate the feasibility of using its technology to topically deliver ISA247. Studies will begin in the next few months and are slated to be completed in one year.

Isotechnika will pay Cellgate a total of $500,000; $200,000 paid upfront and the remainder at predetermined time points.

Once studies are complete, Isotechnika also has the option to license the technology from Cellgate to further develop and commercialize conjugates for topical delivery of ISA247.

"We are excited to be working with a company whose drug is showing great promise in the systemic treatment of psoriasis," Cellgate chairman Linda Sonntag said in a news release.

"It is our hope and expectation that Cellgate's transporter technology will safely and efficaciously expand ISA247's use to the 65% of patients with mild psoriasis and supplement those with moderate to severe psoriasis via topical administration."

Isotechnika, an Edmonton, Alta.-based biopharmaceutical company, develops novel immunosuppressive therapeutics.

Cellgate is a privately held clinical-stage biopharmaceutical company based in Redwood City, Calif.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.